A Randomized, Double-blind, Placebo-controlled, Phase 2B Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
Latest Information Update: 27 Feb 2023
At a glance
- Drugs Gusacitinib (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Acronyms RADIANT
- Sponsors Asana BioSciences
- 20 Oct 2020 Primary endpoint (Change from baseline in Eczema Area and Severity Index (EASI)) has been met, according to an Asana BioSciences media release.
- 20 Oct 2020 Results presented in an Asana BioSciences media release.
- 10 Sep 2019 Status changed from active, no longer recruiting to completed.